tirzepatide availability fda Allows Compounded During Shortage Review FDA declares Mounjaro, Zepbound shortage

This can usually be addressed through modest dietary adjustments

Welcome to Dr

The SURMOUNT trial findings in detail A post hoc analysis of the SURMOUNT program examined psychiatric safety specifically

Key clinical and economic inputsincluding drug acquisition costs, complication costs, utility values, discount rate, and assumptions regarding post-treatment weight regainwere varied

Your healthcare team will likely: Conduct a thorough assessment of your mental health symptoms, including severity, duration, and impact on daily functioning Review your complete medication list to identify any potential drug interactions or contributing factors Evaluate whether symptoms may be related to metabolic changes, such as hypoglycaemia or rapid weight loss Consider whether pre-existing mental health conditions may have been exacerbated Discuss the risks and benefits of continuing Mounjaro versus alternative treatment options Management options may include: Continuing Mounjaro with enhanced monitoring if symptoms are mild and other contributing factors are identified Psychological support such as cognitive behavioural therapy (CBT) or counselling through NHS Talking Therapies (self-referral is possible in many areas) Antidepressant or anxiolytic medication if clinically indicated, prescribed alongside Mounjaro with appropriate monitoring Dose adjustment or temporary discontinuation of Mounjaro if symptoms are severe or a clear temporal relationship is established Referral to specialist services such as mental health teams or endocrinology for complex cases Maintaining regular follow-up appointments is crucial for monitoring both your physical and mental health